EnzymeBioSystems announced that while it continues its early-stage research to obtain an Investigational New Drug Application for methyl amooranin, a product the prevention of breast cancer, management is pursuing other opportunities for the company. Management has been working on developing proprietary OTC product(s) to be sold under the EnzymeBioSystems label.
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |